On December 3, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services (Press release, LabCorp, DEC 3, 2021, View Source [SID1234596440]). The addition of Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The definitive agreement for the transaction was announced on Nov. 18. Specific terms were not disclosed.